In addition, in the CHECKMATE-227 clinical trial, the association of two different immunodrugs (nivolumab plus ipilimumab) showed a similar improvement in PFS in NSCLC patients with at least 10 mutations per megabase [47] when compared to standard-of care chemotherapy; these results were irrespective of PD-L1 expression levels: ORR—45.3% versus 26.9%; mPFS—7.2 months versus 5.5 months; HR for disease progression or death—0.58 (p < 0.001). This evidence concerns the gene CD274 and non-small cell lung carcinoma.